CBD Life Sciences Inc.
CBDL
$0.0004
$0.000.00%
| 03/31/2024 | 03/31/2023 | 03/31/2022 | 09/30/2021 | ||
|---|---|---|---|---|---|
| Revenue | 36.19% | -32.69% | 141.24% | -81.57% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 36.19% | -32.69% | 141.24% | -81.57% | |
| Cost of Revenue | 73.10% | -36.68% | 62.41% | -78.70% | |
| Gross Profit | 4.12% | -28.87% | 359.62% | -84.88% | |
| SG&A Expenses | 72.66% | -86.07% | -83.28% | 788.58% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -61.64% | -- | |
| Total Operating Expenses | 72.78% | -83.32% | -81.28% | 528.58% | |
| Operating Income | -122.98% | 91.71% | 83.75% | -1,316.56% | |
| Income Before Tax | -122.98% | 91.71% | 83.75% | 2.59% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -122.98% | 91.71% | 83.75% | 2.59% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -122.98% | 91.71% | 83.75% | 2.59% | |
| EBIT | -122.98% | 91.71% | 83.75% | -1,316.56% | |
| EBITDA | -578.00% | 98.16% | -- | -- | |
| EPS Basic | -100.00% | 90.48% | 95.07% | 97.15% | |
| Normalized Basic EPS | -100.00% | 92.31% | 95.11% | 67.86% | |
| EPS Diluted | -100.00% | 90.48% | 95.07% | 97.15% | |
| Normalized Diluted EPS | -100.00% | 92.31% | 95.11% | 67.86% | |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 231.01% | 3,310.03% | |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 231.01% | 3,310.03% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
